are employees of Betta Pharmaceuticals which provided partial funding for the study. Other authors declared no conflict of interests. Word count: 4147 Tables/figures: 3 figures, 3 tables, 1 supplemental figures. Statement of translational relevance Non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 21 L858R mutation is considered less sensitive to EGFR tyrosine kinase inhibitors, and new strategies are anticipated to improve the efficacy of targeted therapies among this patient population. This multicenter phase II randomized clinical trial provides an analysis of progression-free survival (PFS) in treatment-naïve EGFR-mutant NSCLC patients on high-dose Research.

Lung cancer is a global disease and a major cause of cancer-related mortality worldwide. Accumulated studies have confirmed the essential role of long non-coding RNAs (lncRNAs) in the occurrence and development of cancers. Meanwhile, there have been reports concerning the role of Small Nucleolar RNA Host Gene 3 (SNHG3) in various cancers. However, there are so far few studies on the function and mechanism of SNHG3 in lung cancer. In the present study, SNHG3 was found to be highly expressed in lung cancer tissues and cells. Downregulation of SNHG3 could inhibit cell proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) process. In addition, SNHG3 was found to have the ability to bind to miR-515-5p. Furthermore, Small Ubiquitin Like Modifier 2 (SUMO2) was identified to be the downstream target of miR-515-5p, which was negatively correlated with miR-515-5p expression. SNHG3 could positively regulate SUMO2 expression by sponging miR-515-5p. In addition, the rescue experiment showed that simultaneous transfection of miR-515-5p or SUMO2 siRNA could reverse the effect of SNHG3 expression on cell proliferation and metastasis. Collectively, our study demonstrates that SNHG3 can act on miR-515-5p in the form of competitive endogenous RNA (ceRNA) to regulate SUMO2 positively and thus affect the proliferation and metastasis of NSCLC cells. Findings in our study support that SNHG3/miR-515-5p/SUMO2 regulatory axis may become a potential therapeutic target for lung cancer.

Sarcoidosis with tracheal mucosa involvement that can lead to cough and other respiratory symptoms, may be a manifestation of sarcoidosis activity, and usually requires drug treatment (including corticosteroid treatment).

No abstract

Abstract. In this paper, we first discuss the convergence of the continued fractions of generalized Rogers-Ramanujan type in the modified sense. Then we prove several equalities concerning these continued fractions. The proofs of our main results are mainly based on the Bauer-Muir transformation. Preliminary materialIf the sequence {S n (0)} of the approximants of the continued fraction b 0 + K(a n /b n ) converges to a point f in the extended complex plane C = C ∪ {∞}, then we call that the continued fraction b 0 + K(a n /b n ) converges to f in the classical sense, and write .).As in [5] or [8], we introduce the following definition.